A study evaluating NSCLC patients seen in community medical oncology practices in New Jersey and Maryland showed between 2013 to 2015, 59% of eligible patients were tested for EGFR mutations, while a second study using data from a national, private health insurance company found testing rates to be around 61% between the years of 2010 to 2012 [19, 20]. Here, EGFR is linked to non-small cell lung carcinoma.